MA46793A - Polythérapies faisant appel à un inhibiteur d'arginase - Google Patents

Polythérapies faisant appel à un inhibiteur d'arginase

Info

Publication number
MA46793A
MA46793A MA046793A MA46793A MA46793A MA 46793 A MA46793 A MA 46793A MA 046793 A MA046793 A MA 046793A MA 46793 A MA46793 A MA 46793A MA 46793 A MA46793 A MA 46793A
Authority
MA
Morocco
Prior art keywords
polytherapies
arginase inhibitor
arginase
inhibitor
Prior art date
Application number
MA046793A
Other languages
English (en)
Inventor
Matthew I Gross
Amani Makkouk
Francesco Parlati
Original Assignee
Calithera Biosciences Inc
Matthew I Gross
Amani Makkouk
Francesco Parlati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc, Matthew I Gross, Amani Makkouk, Francesco Parlati filed Critical Calithera Biosciences Inc
Publication of MA46793A publication Critical patent/MA46793A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA046793A 2016-11-08 2017-11-08 Polythérapies faisant appel à un inhibiteur d'arginase MA46793A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419250P 2016-11-08 2016-11-08
US201762559931P 2017-09-18 2017-09-18

Publications (1)

Publication Number Publication Date
MA46793A true MA46793A (fr) 2019-09-18

Family

ID=60409467

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046793A MA46793A (fr) 2016-11-08 2017-11-08 Polythérapies faisant appel à un inhibiteur d'arginase

Country Status (13)

Country Link
US (1) US11291674B2 (fr)
EP (1) EP3538111B1 (fr)
JP (1) JP2020502259A (fr)
KR (1) KR20190104521A (fr)
CN (1) CN110352063A (fr)
AU (1) AU2017356942A1 (fr)
CA (1) CA3042878A1 (fr)
IL (1) IL266534A (fr)
MA (1) MA46793A (fr)
MX (1) MX2019005402A (fr)
PH (1) PH12019501010A1 (fr)
TW (1) TW201828959A (fr)
WO (1) WO2018089490A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2019211067A1 (en) * 2018-01-28 2020-08-13 Universite De Geneve Arginase suppression for cancer treatment
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
KR102656571B1 (ko) 2018-03-05 2024-04-11 아르커스 바이오사이언시즈 인코포레이티드 아르기나아제 억제제
WO2019177873A1 (fr) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
EP3774843B1 (fr) 2018-03-29 2022-05-25 Molecure SA Dérivés de pipéridine dipeptidiques
KR102587512B1 (ko) * 2018-05-22 2023-10-11 이뮤너티바이오, 인크. 폴록사머를 사용한 nk-92 세포 성장의 최적화
RS65608B1 (sr) * 2018-08-22 2024-07-31 Astrazeneca Ab Inhibitori arginaze i postupci za njihovo korišćenje
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
ES3034676T3 (en) * 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
US20220251116A1 (en) * 2019-02-06 2022-08-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
JP2023500506A (ja) * 2019-11-04 2023-01-06 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN111138358B (zh) * 2019-12-17 2023-04-18 中国药科大学 Usp8抑制剂及其制备方法与应用
US20240002534A1 (en) * 2020-11-30 2024-01-04 Merck Sharp & Dohme Llc Arginase 1 binders for inhibiting arginase 1 activity
EP4251280A4 (fr) * 2020-11-30 2024-11-06 Merck Sharp & Dohme LLC Liants d'arginase 1 pour inhiber l'activité de l'arginase 1
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
US20240350541A1 (en) * 2021-04-06 2024-10-24 Smt Bio Co., Ltd. Composition for preventing or treating extrahepatic bile duct cancer
WO2022238467A1 (fr) * 2021-05-13 2022-11-17 F. Hoffmann-La Roche Ag Prédiction en temps réel de temps de fixation de tissu

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
EP1049660A1 (fr) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions et procedes pour inhiber l'activite de l'arginase
EP1051167A1 (fr) 1998-01-29 2000-11-15 Sepracor, Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
JP2004502948A (ja) 2000-07-06 2004-01-29 ファル　ダイアグノスティクス アルギニン化合物の検出のための方法及びキット
CA2431080A1 (fr) * 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
HRP20191433T1 (hr) 2009-01-26 2019-11-15 Univ Pennsylvania Inhibitori arginaze i metode primjene
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2658580A4 (fr) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc Inhibiteurs de l'arginase et leurs procédés d'utilisation
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP2768509B1 (fr) 2011-10-20 2017-03-22 Glaxosmithkline LLC Azahétérocycles bicycliques substitués et analogues comme modulateurs de la sirtuine
AU2013249790B2 (en) 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
WO2015061752A1 (fr) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
US20180078515A1 (en) 2015-03-20 2018-03-22 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) * 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity

Also Published As

Publication number Publication date
PH12019501010A1 (en) 2019-08-19
KR20190104521A (ko) 2019-09-10
TW201828959A (zh) 2018-08-16
AU2017356942A1 (en) 2019-05-23
US20180161349A1 (en) 2018-06-14
EP3538111B1 (fr) 2022-01-19
WO2018089490A1 (fr) 2018-05-17
CN110352063A (zh) 2019-10-18
JP2020502259A (ja) 2020-01-23
EP3538111A1 (fr) 2019-09-18
IL266534A (en) 2019-07-31
US11291674B2 (en) 2022-04-05
MX2019005402A (es) 2019-12-05
CA3042878A1 (fr) 2018-05-17

Similar Documents

Publication Publication Date Title
MA46793A (fr) Polythérapies faisant appel à un inhibiteur d'arginase
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
EP3761992A4 (fr) Inhibiteurs d'arginase
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3600318A4 (fr) Procédés d'utilisation d'inhibiteurs d'ehmt2
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3732301A4 (fr) Méthodes de traitement du cancer faisant appel à un inhibiteur d'atr
EP3430731A4 (fr) Architecture d'iugw
DK3458802T3 (da) Magasin og kassette
EP3373906A4 (fr) Compositions et procédés destinés à une application sur la peau
EP3798492C0 (fr) Joint de couplage à insertion rapide
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
EP3735467A4 (fr) Vecteurs de la vaccine modifiés
EP3383967A4 (fr) Inhibiteurs d'entartrage solides à libération contrôlée
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
EP3359150A4 (fr) Polythérapie à l'aide d'inhibiteurs de glutaminase et agents immuno-oncologiques
EP3433383A4 (fr) Procédés d'amplification quantitative
EP3449930C0 (fr) Agent de formation de synapses
MA49006A (fr) Inhibiteurs d'ip6k
EP3468947A4 (fr) Dérivés fluorés 2-amino-4-(amino substitué)phényl carbamate
DK3946179T3 (da) Stomiposer
EP3327053A4 (fr) Copolymère à bloc (méth)acrylique
IL285118A (en) Compounds and uses thereof